Related Experiment Video
Updated: Jun 26, 2025
15:28
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
Published on: January 17, 2014
7.8K
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy.
Maxime Mistretta1, Mena Cimino1, Pascal Campagne2
1Institut Pasteur, Université Paris Cité, Microbial Individuality and Infection Laboratory, 75015, Paris, France.
Nature Communications
|May 16, 2024
Summary
Drug-resistant infections are a major threat. This study developed a microfluidic platform to screen for compounds that reduce bacterial variation, making them more susceptible to drugs, including for tuberculosis.
Area of Science:
- Microbiology
- Drug Discovery
- Biotechnology
Background:
- Drug-recalcitrant infections pose a significant global health challenge.
- Bacterial phenotypic variation can lead to antimicrobial resistance, complicating treatment strategies.
- Analyzing individual bacterial cell behavior is crucial but technically challenging for drug discovery.
Purpose of the Study:
- To develop a microfluidic platform for dynamic single-cell screening of compounds that modulate bacterial phenotypic variation.
- To identify compounds that decrease cell-to-cell variation, thereby increasing bacterial population vulnerability to existing drugs.
- To apply this approach to combat Mycobacterium tuberculosis, a major public health threat.
Main Methods:
- Development of a multi-condition microfluidic platform for imaging bacterial growth.
- Implementation of dynamic single-cell screening to identify 'pheno-tuning' compounds.
- Application of the platform and strategy to Mycobacterium tuberculosis.
Main Results:
- The developed platform enables spatiotemporal analysis of bacterial phenotypic variation under different conditions.
- A lead compound was identified that impairs Mycobacterium tuberculosis through a novel mechanism.
- This compound demonstrated synergistic effects, enhancing the efficacy of other anti-tubercular drugs.
Conclusions:
- Harnessing bacterial phenotypic variation is a viable strategy to overcome drug resistance.
- The microfluidic platform facilitates the discovery of compounds that can re-sensitize bacterial populations to antimicrobial therapies.
- This approach offers a promising avenue for developing new treatments against challenging pathogens like Mycobacterium tuberculosis.
